ArticleTurkish journal of obstetrics and gynecology2025
Unexpected hypo-responders in in vitro fertilization: The impact of higher gonadotropin doses on oocyte yield.
Article in Turkish journal of obstetrics and gynecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study assessed the impact of increased initial gonadotropin doses on ovarian stimulation (OS) outcomes in unexpected hypo-responders [Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) 1-2 group] with suboptimal mature oocyte yield, despite normal ovarian reserve markers, during their first OS cycle. Materials and Methods: Conducted at a referral infertility clinic, this observational study included women who retrieved fewer than nine oocytes during their first OS cycle despite gonadotropin doses of 150-225 international unit (IU)/day starting from cycle day two. Women who underwent a second OS cycle following unsuccessful conception were included. Gonadotropin doses were increased to 225 or 300 IU recombinant follicle-stimulating hormone (FSH) (recFSH) based on body mass index. Each patient served as her own control, with first and second OS cycles compared in terms of oocyte yield, follicular output ratio (FORT), and follicle-to-oocyte index (FOI). Results: Among 289 unexpected hypo-responders (12% prevalence), the mean age was 34.2 years, and the mean anti-müllerian hormone level was 3.4 ng/mL. The stimulation duration was similar between cycles (11.2 days). The second OS cycle showed significant improvements in total oocytes, metaphase II oocytes, FORT, FOI, cleavage-stage embryos, and blastocysts (p<0.05). Conclusion: Increasing gonadotropin doses in subsequent cycles improves oocyte yield and embryological outcomes in unexpected hypo-responders (POSEIDON 1-2) with normal ovarian reserve markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.